Actively Recruiting
Phase 1b Study of Subcutaneous Tarlatamab for Safety and Early Effectiveness in Adults with Extensive Stage Small Cell Lung Cancer DeLLphi-308
Led by Amgen · Updated on 2026-06-26
220
Participants Needed
31
Research Sites
156 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and tolerability of subcutaneous SC tarlatamab in people with extensive stage small cell lung cancer ES-SCLC that has progressed or recurred after at least one platinum-based anti-cancer treatment. This Phase 1b study aims to understand how well this treatment is tolerated and its preliminary effects. Participants must have good performance status and adequate organ function to join this study. Tarlatamab is given as a subcutaneous injection in several parts of the study. Part 1 explores different dosing options to find a safe and tolerable dose. In Part 2, participants receive the dose chosen from Part 1 to further evaluate its safety and effects. Part 3 may test alternative dosing schedules based on findings from earlier parts. The treatment is given by injection into the abdomen. Participants will be closely monitored for dose-limiting toxicities, adverse events, vital signs, and laboratory changes for up to 24 months. Blood samples will be taken to study the drugs levels and immune response. Tumor response and survival outcomes will also be tracked using imaging and clinical assessments. Safety and tolerability data will guide future research, and participation can last up to several years depending on individual progress.
CONDITIONS
Brief Title
Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
Research Team
A
Amgen Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here